 |
|
|
| |
A Pragmatic Approach to Optimizing the Efficacy of Elbasvir/Grazoprevir
Using Baseline Viral Load in Participants With Hepatitis C Virus
Genotype 1a Infection: A Post Hoc Analysis of 11 Clinical Trials
|
| |
| |
Reported by Jules Levin
AASLD - The Liver Meeting 2017; Washington, DC; October 20-24, 2017
Lawrence Serfaty1; Ira Jacobson2; Jurgen Rockstroh3; Frederick L. Altice4;
Peggy Hwang5; Eliav Barr5; Michael Robertson5; Barbara Haber5
1Service d'Hepatologie, Hopital Saint-Antoine, Universite Pierre & Marie Curie, Paris, France; 2Mount Sinai Beth Israel and Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Bonn University Hospital, Bonn, Germany; 4Yale University, New Haven, CT, USA; 5Merck & Co., Inc., Kenilworth, NJ, USA
CKD, chronic kidney disease; FAS, full analysis set; mFAS, modified full analysis set; TE, treatment-experienced; TN, treatment-naive.
a Reasons for exclusion included: 3 reinfections, 10 lost to follow-up, 4 withdrawal by participants, 3 deaths, 3 discontinuations due to adverse events,
and 1 discontinuation due to noncompliance.
BMI, body mass index.
a Reasons for exclusion included: 3 reinfections, 10 lost to follow-up, 4 withdrawal by participant, 3 deaths, 3 discontinuations due to adverse events,
and 1 discontinuation due to noncompliance.
bTreatment-experienced participants had previously received peginterferon/RBV.
aExcludes participants with nonvirologic failure or reinfections.
bTreatment difference (95% CI) is SVR12 for <800,000 IU/mL minus SVR12 for ≥800,000 IU/mL, based on the Miettinen & Nurminen method.
|
| |
|
|
|
|
|
